Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Therapeutic Drug Monitoring

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FTD.0000000000000384PMID 28691952
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study

  2016cited by this paper
• Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations

  2016cited by this paper
• Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis

  2015cited by this paper
• Key findings towards optimising adalimumab treatment: the concentration-effect curve.

  2015cited by this paper
• Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized Treatment.

  2015cited by this paper
• Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation.

  2014cited by this paper
• Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation

  2014cited by this paper
• Determinants of drug survival for etanercept in a long‐term daily practice cohort of patients with psoriasis

  2014cited by this paper
• Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up

  2014cited by this paper
• Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single‐centre, cohort study

  2013cited by this paper
• Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases

  2013cited by this paper
• Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up

  2013cited by this paper
• Monitoring Antigen-Specific Biologics: Current Knowledge and Future Prospects

  2013cited by this paper
• Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease

  2012cited by this paper
• The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

  2012cited by this paper
• Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

  2011cited by this paper
• High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation.

  2010cited by this paper
• Evaluating non‐adherence to immunosuppressant medications in pediatric liver transplant recipients

  2008cited by this paper
• The pharmacokinetics of etanercept in patients with end‐stage renal disease on haemodialysis

  2005cited by this paper
• Psoriasis assessment tools in clinical trials

  2005cited by this paper
• Unaltered Etanercept Pharmacokinetics With Concurrent Methotrexate in Patients With Rheumatoid Arthritis

  2004cited by this paper
• Etanercept as monotherapy in patients with psoriasis.

  2003cited by this paper
• Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells.

  2002cited by this paper

• Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study

  2023cites this paper
• Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis

  2022cites this paper
• Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta

  2020cites this paper
• Overcoming Compensatory Mechanisms toward Chronic Drug Administration to Ensure Long-Term, Sustainable Beneficial Effects

  2020cites this paper